Pfizer, U.S. health officials to discuss COVID boosters on Monday
-company
Send a link to a friend
[July 12, 2021]
WASHINGTON (Reuters) - COVID-19
vaccine maker Pfizer Inc will meet with federal health officials as soon
as Monday to discuss the need for a booster dose of the coronavirus
vaccine as it prepares to seek authorization, the company said on
Sunday.
The meeting comes days after the drugmaker and its partner BioNTech SE
announced plans to seek U.S. and European regulatory approval for a
third dose of their COVID-19 shot amid the spread of variants and data
they said showed heightened risk of infection six months after initial
inoculation.
That push prompted a quick response from the U.S. Food and Drug
Administration and the Centers for Disease Control and Prevention,
saying Americans do not need a booster right now.
On Monday, Pfizer is scheduled to meet with representatives of the FDA,
a company spokesperson said. The meeting was first reported by the
Washington Post.
Representatives for the U.S. Department of Health and Human Services did
not immediately respond to a request for comment.
Anthony Fauci, President Joe Biden’s chief medical adviser who also
directs the National Institute of Allergy and Infectious Diseases, as
well as the heads of the National Institutes of Health and the CDC were
also among those invited to the briefing, which could move to another
day, according to the Post's report.
Fauci, in several television interviews on Sunday, said U.S. health
officials were not dismissing the possible future need for boosters --
especially as breakthrough infections among those who have been
vaccinated have emerged -- but that more data is needed for any formal
recommendation.
"There's a lot of dynamic things going on right now," he told ABC News'
"This Week" program.
"There are studies being done now ongoing as we speak about looking at
the feasibility about if and when we should be boosting people...
there's a lot of work going on to examine this in real time," he added
on CNN's "State of the Union."
[to top of second column]
|
U.S. first lady Jill Biden looks on as Alfred Lee Smith is
vaccinated with the Johnson & Johnson COVID-19 vaccination at a
vaccination facility at Alfred E. Beach High School in Savannah,
Georgia, U.S. July 8, 2021. Jim Watson/Pool via REUTERS
Despite the FDA and CDC's statement, "that doesn't
mean that we're not very, very actively following and gathering all
of this information to see if and when we might need it and if and
when we do, we'll have everything in place to do it."
U.S. health officials are still struggling to get people in some
areas to receive their initial inoculations as the highly contagious
Delta variant has grown to be the nation's dominant strain, with
COVID-19 cases rising mostly among the unvaccinated.
European officials has also said vaccines currently seem protective
against variants. Canada has also said it is monitoring variants and
the possible need for boosters.
While some scientists have also questioned the need for booster
shots, others have said they could be beneficial for the elderly and
other vulnerable populations, although it is unclear when they would
be needed.
Some public health experts have also expressed concern that
authorizing boosters in wealthy developed nations while other
countries are still struggling against initial inoculations will
further exacerbate vaccine inequity.
(Reporting by Susan Heavey and Chris Prentice; additional reporting
by Linda So; Editing by Chizu Nomiyama)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|